title: Reply to: The importance and challenge of pediatric trials of hemophilia drugs.
authors.affiliation: 1] IRCCS Ca' Granda Foundation Maggiore Policlinico Hospital, Milan, Italy. [2] Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
authors.forename: Flora
authors.initials: F
authors.lastname: Peyvandi
authors.affiliation: 1] Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands. [2] Department of Thrombosis and Haemostasis, Leiden University Medical Center, Leiden, The Netherlands.
authors.forename: Frits R
authors.initials: FR
authors.lastname: Rosendaal
authors.affiliation: European Haemophilia Consortium, Brussels, Belgium.
authors.forename: Brian
authors.initials: B
authors.lastname: O'Mahony
authors.affiliation: Scientific Direction, IRCCS Ca' Granda Foundation Maggiore Policlinico Hospital, Milan, Italy.
authors.forename: Pier Mannuccio
authors.initials: PM
authors.lastname: Mannucci
mesh_terms: D017277:Drug Approval / Q000331:legislation & jurisprudence*; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans